Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855 [EXTENSION OF 700221438]

Next Previous
Trial Profile

Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855 [EXTENSION OF 700221438]

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelonicline (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Adverse reactions
  • Sponsors AbbVie

Most Recent Events

  • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
  • 21 Sep 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
  • 23 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network: 15207).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top